Table 4.

Duration of aspirin use¹ and risk for developing incident advanced fibrosis², among patients with NAFLD fibrosis stage 0-2 at enrollment (n=317)

	Duration of daily aspirin use (years)1
	Non-regular use (ref.)	0 to <2 years	2 to <4 years	≥4 years	P for trend3
No. of patients with composite endpoint2	54	11	12	9
Age- and sex-adjusted* HR (95% CI)	1	0.85 (0.65-1.10)	0.60 (0.42-0.81)	0.47 (0.34-0.69)	<0.0001
Multivariable Model¥; HR (95% CI)	1	0.90 (0.68-1.20)	0.64 (0.45-0.86)	0.50 (0.35-0.73)	0.026

Abbreviations: NAFLD, nonalcoholic fatty liver disease; No., number; HR, hazard ratio; CI, confidence interval

^*Model 1: see footnote for Table 3.

^¥Multivariable Model: see footnote for Table 3.

¹Aspirin use was defined as daily use of aspirin. Less frequent use or never-use was defined as non-regular use. Aspirin use data was ascertained and updated at each clinical follow-up visit and modeled as a time-varying exposure.

²Incident advanced fibrosis was defined as the first recorded follow-up FIB-4 Index >2.67 or NFS >0.67 or APRI > 1.0.

³P-trend across increasing categories of duration, among daily aspirin users.